FY2026 EPS Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Cut by Wedbush

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Research analysts at Wedbush decreased their FY2026 earnings per share (EPS) estimates for shares of Fennec Pharmaceuticals in a research report issued on Tuesday, August 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $2.31 per share for the year, down from their prior forecast of $2.57. Wedbush currently has a “Outperform” rating and a $14.00 price objective on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.36 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2027 earnings at $2.77 EPS.

FENC has been the subject of several other research reports. HC Wainwright dropped their price target on shares of Fennec Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, May 15th. Craig Hallum lowered their price objective on shares of Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday.

Fennec Pharmaceuticals Trading Up 4.7 %

Shares of FENC stock opened at $5.58 on Wednesday. The firm’s 50-day simple moving average is $6.33 and its 200-day simple moving average is $8.30. The company has a debt-to-equity ratio of 9.86, a current ratio of 6.93 and a quick ratio of 6.72. Fennec Pharmaceuticals has a 1-year low of $5.26 and a 1-year high of $11.92. The firm has a market cap of $152.49 million, a P/E ratio of 186.00 and a beta of 0.29.

Fennec Pharmaceuticals (NASDAQ:FENC) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $7.26 million during the quarter, compared to analyst estimates of $13.67 million. Fennec Pharmaceuticals had a negative return on equity of 39.41% and a net margin of 6.33%. During the same period in the previous year, the business posted ($0.21) earnings per share.

Institutional Trading of Fennec Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Gendell Jeffrey L grew its stake in Fennec Pharmaceuticals by 7.1% during the first quarter. Gendell Jeffrey L now owns 302,478 shares of the company’s stock worth $3,364,000 after buying an additional 20,000 shares during the period. Essex Investment Management Co. LLC purchased a new stake in Fennec Pharmaceuticals during the 1st quarter worth $1,604,000. Worth Venture Partners LLC increased its holdings in Fennec Pharmaceuticals by 52.7% in the 4th quarter. Worth Venture Partners LLC now owns 141,500 shares of the company’s stock valued at $1,588,000 after purchasing an additional 48,864 shares in the last quarter. Bank of New York Mellon Corp raised its position in Fennec Pharmaceuticals by 42.8% in the second quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock valued at $420,000 after purchasing an additional 20,602 shares during the period. Finally, WINTON GROUP Ltd acquired a new position in shares of Fennec Pharmaceuticals during the second quarter worth about $409,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.